1228 — Canbridge Pharmaceuticals Balance Sheet
0.000.00%
- HK$1.07bn
- HK$1.11bn
- CNY85.10m
Annual balance sheet for Canbridge Pharmaceuticals, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 361 | 746 | 463 | 137 | 10.5 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 25 | 27.9 | 19.1 | 39.5 | 26.6 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 391 | 812 | 505 | 210 | 45.4 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 15.6 | 29.5 | 145 | 109 | 3.64 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 586 | 893 | 702 | 395 | 117 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 108 | 186 | 278 | 328 | 483 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 2,332 | 199 | 393 | 435 | 591 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | -1,746 | 693 | 309 | -39.8 | -474 |
| Total Liabilities & Shareholders' Equity | 586 | 893 | 702 | 395 | 117 |
| Total Common Shares Outstanding |